Antisense oligonucleotides

German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling. Precise modulation of TGF-B pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications.The company’s lead compound, ISTH0036, is in clinical development in ophthalmology.On the podcast this week we chat with René Rückert, chief operating officer at Isarna Therapeutics, who explains TGF-B and antisense oligonucleotides’ role in tackling disease.00:59-02:45: About Isarna Therapeutics02:45-05:05: What is transforming growth factor beta?05:05-06:16: Why is TGF a good target?06:16-09:00: What are antisense oligonucleotides?09:00-10:02: What are antisense oligonucleotides useful for treating?10:02-11:21: What advantages do antisense oligonucleotides have?11:21-13:00: How can antisense oligonucleotides be delivered?13:00-14:58: Are antisense oligonucleotides still being researched?14:58-16:31: Are there challenges with using antisense oligonucleotides?16:31-16:56: Are many companies working on antisense oligonucleotides?16:56-18:06: Are antisense oligonucleotides best used as a monotherapy or with other treatments?18:06-20:42: What is Isarna’s pipeline?20:42-22:47: How does your AMD treatment work?22:47-23:50: What is the timeline for your treatment?23:50-26:34: What can patients expect?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter